Pfizer-BioNTech announce their vaccine is 95% effective

On November 18, 2020 Pfizer and BioNTech announced the final analysis of their COVID-19 vaccine Phase III clinical trial data shows it is 95% effective with no safety concerns.  Pfizer filed for emergency use authorization with the FDA “within days” of this announcement.

“Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,” Pfizer and its German partner BioNTech said in a joint statement. [1]